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Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Using another member of the TNF-R family, the transmembrane activator, calcium modulator, and cyclophilin ligand interactor (TACI)-Fc, we observed a similar inhibition of DC generation from peripheral blood monocytes ( Figure 1A top) as reported by You et al with DcR3-Fc. 1, 6 It is noteworthy that TACI, like DcR3, has an HSPG-binding domain. 7 By contrast, B-cell maturation antigen (BCMA)-Fc that binds the same ligands as TACI-Fc but has no HSPG binding domain 7 and control IgG1 did not affect DC generation. Such inhibition of DC generation was also observed with a member of the TNF family, a proliferation-inducing ligand (APRIL) also bearing an HSPG binding domain 8 fused to the same Fc of IgG1 (Fc-APRIL; Figure 1A bottom). A mutant of the latter molecule without its HSPG binding domain, Fc-APRIL H98 , 8 or the wildtype molecule oligomerized by a non-Ig moiety, the collagen domain of adiponectin, ACRP-APRIL, 9 failed to inhibit DC generation in spite of binding to DC very efficiently ( Figure 1B 1, 4 and enhance osteoclast differentiation. 5 These experiments will provide information to support, or against, their second speculation. No doubt oligomerized DcR3 is more potent than monomeric DcR3, 3 and DcR3 fused with Fc or another tag might enhance DcR3 activity by increasing stability, dimerization, or oligomerization. However, endogenous DcR3 without Fc still has effects similar to DcR3.Fc because the modulatory effects of DcR3.Fc are also observed in transgenic mice overexpressing DcR3. 6, 7 Recently, we further demonstrated that DcR3.Fc is able to down-regulate the expression of the master regulator of MHC-II expression (CIITA) in tumor-associated macrophages (TAM) in vitro, and this is confirmed in the TAMs derived from transgenic mice and cancer patients with up-regulated DcR3. 8 Therefore, like APRIL, 9 endogenous DcR3 might be able to bind to extracellular matrix or to proteoglycan-positive cells to induce oligomerization, and is as potent as, or similar to, DcR3.Fc.
In addition to interacting with proteoglycan, DcR3 also interacts and neutralizes the functions of 3 members of the tumor necrosis factor (TNF) superfamily: Fas ligand (FasL), 10 LIGHT, 11 and TL1A. 12 Previous studies have shown that DcR3 inhibits FasL-mediated apoptosis 7 and enhance angiogenesis via neutralizing TL1A in vivo. 13 Therefore, the newly identified action in DC apoptosis is one of the pleiotropic effects of DcR3 to promote tumor growth.
Several reports have shown that higher serum level of DcR3 correlates with poor prognosis of cancer patients, 8, [14] [15] [16] and the presence of DcR3 correlates with resistance to 5-fluorouracilbased adjuvant chemotherapy. 17 Therefore, serum level of DcR3 is not only a useful marker to predict cancer prognosis, but is also an important parameter to predict tumor resistance to certain chemotherapy. 
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